Companies / Silence Therapeutics plc

Silence Therapeutics plc

Nasdaq: SLNCIK 1479615LONDON

Financials · FY2025

Revenue$559.0K
Net income$-88.61M
Total debt
Cash$72.05M
Diluted EPS$-0.63
Shares outstanding141.7M

Ownership

141.7M shares outstanding · as of Jul 31, 2026
13.8%Institutions
Ownership
Institutions13.85%19,627,253
Public float86.15%122,112,784

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
Hellums Rhonda LynetteChief Financial Officer · Director
Lemus DavidDirector
Romano Steven J.EVP and Chief R&D Officer

Institutional holders 60

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q4 2025
as of
Cantor Fitzgerald, L. P.
13F manager
ExitADR$-4.16M-801K
-100.00%
0
low
Q1 2026
as of
Millennium Management LLC
13F manager
AddADR$2.18M+415K
+62.86%
1,074,191
0.76% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
AddADR$1.61M+147K
+200.63%
219,917
0.16% of shares
low
Q1 2026
as of
Great Point Partners, LLC
13F manager
AddADR$1.12M+212K
+26.29%
1,020,489
0.72% of shares
low
Q1 2026
as of
BNP Paribas Financial Markets
13F manager
AddADR$714.8K+136K
+1127.80%
147,668
0.10% of shares
low
Q2 2026
as of
Quadrature Capital Ltd
13F manager
AddADR$700.0K+64K
+117.23%
118,129
0.08% of shares
low
Q2 2026
as of
Persistent Asset Partners Ltd
13F manager
NewADR$166.6K+15K
15,170
0.01% of shares
low
Q1 2026
as of
Two Sigma Investments, LP
13F manager
TrimADR$-122.0K-23K
-58.82%
16,203
0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Lombard Odier Asset Management (USA) CorpPassive13G/A

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
SLNADREquity82686Q101BBG00WVTHPN2